Paris, France - Enoxaparin (Lovenox, Sanofi-Aventis) seems to be associated with a lower risk of cardiovascular outcomes compared with unfractionated heparin (UFH) in patients with STEMI undergoing ...
LONDON, June 5 (Reuters) - Doctors in Europe can continue to use Sanofi-Aventis SA's heparin medicine Lovenox, despite low levels of contamination found in some batches of the product, the European ...
Lovenox (enoxaparin) is a prescription drug used to prevent or treat certain types of blood clots. Lovenox’s cost may depend on factors such as your dosage, whether you have health insurance, and how ...
Sanofi-Aventis has won FDA priority review for a new indication for its blockbuster blood thinner Lovenox.The FDA will review Lovenox for treatment of patients suffering acute ST-segment elevation ...
Leuven, Belgium - The combination of full-dose tenecteplase (TNKase/Metalyse® - Genentech/Boehringer Ingelheim) and enoxaparin (Lovenox/Clexane® - Aventis) has emerged as the surprise winner in the ...
(Reuters) - The U.S. Food and Drug Administration issued a new warning on the use of the anticoagulant Lovenox in patients fitted with a spinal catheter because of the risk of spinal column bleeding ...
Techdow USA is introducing 30 mg, 40 mg, 60 mg, 80 mg, 100 mg, 120 mg and 150 mg strengths of generic Enoxaparin Sodium (Preservative Free) Prefilled Syringes, which is the generic of Sanofi-Aventis’ ...
Shares of Momenta took a hit after the company warned that its development of a generic version of Sanofi's blood thinner Lovenox is likely to take longer than expected. Shares slid 15 percent on the ...
Hosted on MSN
Foods to Avoid When Taking Enoxaparin
If you have deep vein thrombosis or a pulmonary embolism, or if you had a certain kind of heart attack (among other conditions), your doctor may prescribe the blood thinner enoxaparin (Lovenox), per ...
Jerusalem, Israel, January 25, 2011 - Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that it has received correspondence from the U.S. Food and Drug Administration (FDA) regarding ...
JERUSALEM--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) commented today on the U.S. Food and Drug Administration’s response to a citizen petition questioning the approval ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback